- Home
- AUUD vs LIPO Comparison
AUUD vs LIPO Comparison
Compare AUUD & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- LIPO
- Stock Information
- Founded
- AUUD 2012
- LIPO 2005
- Country
- AUUD United States
- LIPO United States
- Employees
- AUUD N/A
- LIPO N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- LIPO Health Care
- Exchange
- AUUD Nasdaq
- LIPO Nasdaq
- Market Cap
- AUUD 2.9M
- LIPO 3.1M
- IPO Year
- AUUD 2021
- LIPO 2022
- Fundamental
- Price
- AUUD $3.37
- LIPO $2.65
- Analyst Decision
- AUUD
- LIPO
- Analyst Count
- AUUD 0
- LIPO 0
- Target Price
- AUUD N/A
- LIPO N/A
- AVG Volume (30 Days)
- AUUD 215.8K
- LIPO 176.2K
- Earning Date
- AUUD 05-13-2025
- LIPO 05-08-2025
- Dividend Yield
- AUUD N/A
- LIPO N/A
- EPS Growth
- AUUD N/A
- LIPO N/A
- EPS
- AUUD N/A
- LIPO N/A
- Revenue
- AUUD N/A
- LIPO $536,357.00
- Revenue This Year
- AUUD N/A
- LIPO N/A
- Revenue Next Year
- AUUD N/A
- LIPO N/A
- P/E Ratio
- AUUD N/A
- LIPO N/A
- Revenue Growth
- AUUD N/A
- LIPO 19.29
- 52 Week Low
- AUUD $2.88
- LIPO $1.97
- 52 Week High
- AUUD $33.32
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- AUUD 40.10
- LIPO 57.23
- Support Level
- AUUD $2.88
- LIPO $2.25
- Resistance Level
- AUUD $6.49
- LIPO $2.44
- Average True Range (ATR)
- AUUD 0.86
- LIPO 0.22
- MACD
- AUUD -0.03
- LIPO 0.04
- Stochastic Oscillator
- AUUD 13.57
- LIPO 88.39
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.